The permission of LG Chem's rheumatoid arthritis treatment Eucept (Etanercept) will be changed. The MFDS will prepare an order (proposal) to change the permission items based on the results of the re-examination of Eucept Prefilled Syringe and Eucept Auto Injector and inquire about opinions until the 17th. Eucept is LG Chem's first antibody-drug and was approved in Korea in March 2018 as a treatment for rheumatoid arthritis, psoriatic arthritis, axial spinal arthritis, and psoriasis. LG Chem started developing Eucept in 2010 and launched it in Japan and Korea, even before the biosimilar market was formed. Eucept was selected as a national project for the Daedeok Special Zone Strategic Industry R&D Project hosted by t